Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer’s Disease Neuroimaging Initiative

Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia

(2020) Shorena Janelidze et al.   NATURE MEDICINE

Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration

(2020) Elisabeth H. Thijssen et al.   NATURE MEDICINE

Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts

(2020) Thomas K Karikari et al.   LANCET NEUROLOGY

The transformative potential of plasma phosphorylated tau

(2020) Clifford R Jack   LANCET NEUROLOGY

Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders

(2020) Antoine Leuzy et al.   JAMA Neurology

Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer’s disease

(2020) Niklas Mattsson-Carlgren et al.   Science Advances

Plasma p-tau181 accurately predicts Alzheimer’s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline

(2020) Juan Lantero Rodriguez et al.   ACTA NEUROPATHOLOGICA

Diagnostic and prognostic value of serum NfL and p-Tau181 in frontotemporal lobar degeneration

(2020) Alberto Benussi et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimer’s disease: a longitudinal cohort study

(2020) Antoinette O’Connor et al.   MOLECULAR PSYCHIATRY

Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease

(2019) Niklas Mattsson et al.   JAMA Neurology

Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease

(2019) Bernard J. Hanseeuw et al.   JAMA Neurology

Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography

(2018) Michelle M. Mielke et al.   Alzheimers & Dementia

CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts

(2018) Oskar Hansson et al.   Alzheimers & Dementia

NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease

(2018) Clifford R. Jack et al.   Alzheimers & Dementia

Update on biomarkers for amyloid pathology in Alzheimer's disease

(2018) Nicholas J Ashton et al.   Biomarkers in Medicine

Assay of Plasma Phosphorylated Tau Protein (Threonine 181) and Total Tau Protein in Early-Stage Alzheimer’s Disease

(2018) Che-Chuan Yang et al.   JOURNAL OF ALZHEIMERS DISEASE

High performance plasma amyloid-β biomarkers for Alzheimer’s disease

(2018) Akinori Nakamura et al.   NATURE

Tau Kinetics in Neurons and the Human Central Nervous System

(2018) Chihiro Sato et al.   NEURON

Prevalence and Outcomes of Amyloid Positivity Among Persons Without Dementia in a Longitudinal, Population-Based Setting

(2018) Rosebud O. Roberts et al.   JAMA Neurology

Current state of Alzheimer’s fluid biomarkers

(2018) José Luis Molinuevo et al.   ACTA NEUROPATHOLOGICA

Biomarkers for tau pathology

(2018) Michael Schöll et al.   MOLECULAR AND CELLULAR NEUROSCIENCE

Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer’s disease and down syndrome

(2017) Harutsugu Tatebe et al.   Molecular Neurodegeneration

Blood-based NfL

(2017) Oskar Hansson et al.   NEUROLOGY

Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity

(2017) Sebastian Palmqvist et al.   Nature Communications

Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease

(2017) Niklas Mattsson et al.   JAMA Neurology

Plasma tau in Alzheimer disease

(2016) Niklas Mattsson et al.   NEUROLOGY

Plasma β-amyloid in Alzheimer’s disease and vascular disease

(2016) Shorena Janelidze et al.   Scientific Reports

How Does the Accuracy of Intracranial Volume Measurements Affect Normalized Brain Volumes? Sample Size Estimates Based on 966 Subjects from the HUNT MRI Cohort

(2015) T.I. Hansen et al.   AMERICAN JOURNAL OF NEURORADIOLOGY

Cerebrospinal fluid tau and amyloid-β1-42in patients with dementia

(2015) Tobias Skillbäck et al.   BRAIN

Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia

(2015) Willemijn J. Jansen et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Longitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNI

(2013) Jon B. Toledo et al.   ACTA NEUROPATHOLOGICA

Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers

(2013) Clifford R Jack et al.   LANCET NEUROLOGY

Changes in Amyloid-  and Tau in the Cerebrospinal Fluid of Transgenic Mice Overexpressing Amyloid Precursor Protein

(2013) L. F. Maia et al.   Science Translational Medicine

Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010

(2012) Thomas G. Beach et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

FreeSurfer

(2012) Bruce Fischl   NEUROIMAGE

Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI

(2009) Susan M. Landau et al.   NEUROBIOLOGY OF AGING

Alzheimer's Disease Neuroimaging Initiative (ADNI): Clinical characterization

(2009) R. C. Petersen et al.   NEUROLOGY